RE: Wouldn’t22 Aug 2020 19:46
looking through the current pandemic to the long term potential of:
1) Traumakine (ARDS is a major unmet need)
2) Clevegen (nearly 2m patients per year on just four of the cohorts in the expanded study - ‘one ring to rule them all’)
3) The secret weapon. Not in current corporate presentation but hidden at bottom of page 2 in Juho Jalkanen’s presentation on 04/02/20 is the following bullet point..... ‘2018 - onwards: Ground breaking discovery of the functionality of lymph node lymphatics leading to several targets to prevent cancer metastasis’. Sounds like a secret weapon to me.
Ok, the further down the list you go, the further we are from market and the more you would have to factor in the risks. But even so, add that lot up (applying whatever risk factors you like) and I’d say we’re somewhat undervalued!